Navigation Links
Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
Date:2/19/2009

PHILADELPHIA, Pennsylvania and DUBLIN, Ireland, February 19 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the year to December 31, 2008 - a year which has seen significant growth in Shire's new product portfolio.

    Financial Highlights

                                   Full Year 2008 (1)         Q4 2008 (1)

    Product sales                    $2.75bn    + 27%      $0.70 bn   + 7%(3)
    Product sales
     (excluding ADDERALL XR(R))      $1.65bn    + 45%      $0.43 bn  + 12%(3)
    New product sales (2)            $1.00bn   36% of      $0.27 bn    38% of
                                              product                 product
                                                sales                   sales
    Total revenues                   $3.02bn    + 24%      $0.77 bn   + 6%

    Non GAAP diluted earnings per
    ADS                              $3.86      + 36%      $1.01      + 9%
    US GAAP diluted earnings per
    ADS                              $0.86   + $8.92       $0.78     - 30%
    Dividends (in US$ terms)     9.91c per       +15%        n/a      n/a
                                  ordinary
                                     share


    (1) All growth figures compare 2008 results with the same period in 2007.
        New product sales shown as a percentage of 2008 full year/Q4 total
        Product sales.

    (2) New product sales comprise DAYTRANA(R), ELAPRASE(R), FIRAZYR(R),
        FOSRENOL(R), LIALDA(R) / MEZAVANT(R) and VYVANSE(R)

    (3) Q4 year-on-year product sales growth has been impacted by movements
        in foreign exchange rates - on a constant exchange rate ("CER") basis
        growth in product sales was 10%, and growth in product sales
        excluding ADDERALL XR was 18%. CER growth
'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
2. Shire plc: Change to Directors Details
3. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
4. Shires New Product Portfolio Delivers Strong Quarterly Performance
5. Change of Name to Shire plc
6. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
7. Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
8. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
9. Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
10. Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
11. Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... - Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX: ... and,Trademark office has issued a patent for ... development. The newly issued patent, U.S. Patent,# ... matter of PX-867,and pharmaceutical preparations containing PX-867., ...
... 3SBio Inc.,(Nasdaq: SSRX ) ("3SBio" or ... focused on researching, developing, manufacturing and,marketing biopharmaceutical ... board of directors has approved a share ... 3SBio to purchase up to US$20 million ...
... Resubmit With New Data from Ongoing Studies, CAMBRIDGE, ... today announced the withdrawal of the European application,to extend ... elderly patients with acute myeloid leukemia (AML). This,application and ... by Bioenvision,Ltd. before the company was acquired by Genzyme ...
Cached Biology Technology:Oncothyreon announces issuance of patent for PX-867 2Oncothyreon announces issuance of patent for PX-867 33SBio Inc. Approves Share Repurchase Program 2Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients 2Genzyme Withdraws Bioenvision's European Filing of Evoltra(R) in Elderly AML Patients 3
(Date:12/5/2014)... Calif. , Dec. 4, 2014 ... has boosted investments in new testing and inspection ... also given rise to a range of innovative ... the requirements of Generation Y, which is generally ... As a result, product development strategies of test ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... the possible inventory of molecules available to the ... research professor at Arizona State University, found that ... blazing fireball over California last year, contains organic ... findings suggest a far greater availability of extraterrestrial ...
... of Pharmaceutical Scientists (AAPS) WHAT: ... share the latest groundbreaking scientific discoveries and industry developments ... event will bring together more than 8,000 scientists, business ... initiatives underway aimed at improving global health through advances ...
... have discovered a new defense mechanism that the immune ... how a novel protein unexpectedly activates an immune response ... get rid of tumour cells. This research was done ... July 2013 in Nature Immunology ., 2. The immune ...
Cached Biology News:ASU scientists strike scientific gold with meteorite 2Novel mechanism discovered in first line of immune defense 2
For removal of the zona pellucida. Sterile, Mouse Embryo tested...
A substrate for all AChE-based EIA kits....
... Degranulation, the secretion of cytoplasmic granules, ... inflammatory response of leukocytes (e.g. basophils, ... addition to histamine, these secretory granules ... cytokines, chemokines, and many proteases (Hallgren, ...
... AGI provides both long and short-term enriched ... animals in both quarantine and non-quarantine settings ... are also available utilizing our state-of-the-art social ... is equipped with on site CDC quarantine ...
Biology Products: